Adcytherix has raised EUR 30 million (USD 32.2 million) in a seed funding round led by Pontifax and supported by Pureos Bioventures, RA Capital Management, Dawn Biopharma, and company management.
The funds raised are intended to be channeled towards R&D efforts to develop new antibody-drug conjugates (ADCs) for treating diseases with a high unmet need, such as cancer.
Based in France, Adcytherix is a biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) to treat diseases with a high unmet need.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.